Phase 4 N=411 On Versus Off Pump Myocardial Revascularization Study
Coronary Artery Disease
Primary: Number of Patients With Post-operative Combined Endpoint (i.e. With One or More of the Following) — 13; 26 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 4 N=91 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
Arteriosclerosis of Coronary Artery Bypass Graft
Primary: Technical Success (Graft Patency) in a MICS Approach — 100 percentage of grafts
N/A N=260 Tranexamic Acid in Off-pump Coronary Surgery
Off Pump Coronary Artery Bypass Surgery
Primary: Number of Patients Required Allogenic Red Blood Cells Transfusion — 37; 54 participants — p=<0.05
N/A N=2,203 ROOBY Trial Follow-up Extension
All Cause Mortality · MACE
Primary: Long-term All Cause Mortality Between On-pump and Off-pump Patients. — 131; 168; 298; 342 Participants
N/A N=224 A Prospective Randomized Study for Comparison of Y-Composite Grafts
Coronary Artery Disease
Primary: 1 Year Graft Patency Rates — 97.1; 97.1 percentage of distal anastomoses
Phase 2 N=56 Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
Coronary Artery Bypass Grafting · Cardiopulmonary Bypass · Reperfusion Injury
Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2
Phase 2 N=100 Quercetin in Coronary Artery By-pass Surgery
Coronary Artery Disease
Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
N/A N=1,150 Randomized Endo-Vein Graft Prospective
Coronary Artery Bypass Grafting
Primary: Incidence of First MACE During Active Follow-up Period. — 80; 89 Participants — p=0.47
N/A N=1,500 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
Coronary Disease · Coronary Stenosis
Primary: MACCE — 80; 51 Participants — p=0.35
Phase 2 N=448 Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia
Coronary Artery Bypass Surgery
Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05
Phase 2 N=11 AZD8601 Study in CABG Patients
Heart Failure
Primary: Number of Subjects With Adverse Events — 7; 4 Participants
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=40 Intraoperative Echocardiography in Low-Risk CABG Surgery
Heart Diseases · Coronary Artery Disease · Chest Pain
Primary: Enrollment and Randomization Feasibility — 40 Participants
Phase 3 N=2,136 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Cardiovascular Diseases · Coronary Disease · Heart Failure, Congestive
Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12
N/A N=453 Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery
Cardiovascular Diseases · Coronary Disease · Heart Diseases
Primary: Generic Mental Health-Related Quality of Life — 50.0; 46.2; 57.2 units on a scale
Phase 4 N=500 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass · Antiplatelet Agents
Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts
N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
N/A N=104 Does MiECC Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?
Acute Kidney Injury
Primary: Acute Kidney Injury — 7; 41; 9; 40 participants — p=0.377
N/A N=14 Modified Perfusion for Neonatal Aortic Arch Reconstruction
Aortic Arch Hypoplasia or Atresia
Primary: Intestinal Fatty Acid Binding Protein and C-reactive Protein
N/A N=54 Transitional Rehabilitation in CABG Patients
Coronary Artery Disease · Coronary Artery Bypass Graft Surgery
Primary: Short Physical Performance Battery — 7.33; 8.00; 11.44; 10.90 units on a scale
Phase 2 N=389 Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
Coronary Disease · Heart Diseases · Cardiovascular Diseases
Primary: Cognitive Function — 0.07; 0.12 Continuous cognitive change score
N/A N=37 Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI
Coronary Artery Disease (CAD)
Primary: Index of Microcirculatory Resistance (IMR) — 15; 25 mmHg·s
N/A N=200 Cerebral Oximetry and Neurocognitive Functions in Cardiosurgical Patients
Coronary Artery Disease · Postoperative Cognitive Dysfunction · Neurological Impairment
Primary: Difference in Incidence of Cognitive Impairment Between Groups. Change Between Preoperative and Postoperative Cognitive Function Was Assessed by Performing Standardized…
Phase 2 N=33 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass Graft · Cardiopulmonary Bypass
Primary: Incidence of Adverse Events — 3; 3; 5; 4 participants
Phase 2 N=221 Maintenance of Platelet Inhibition With Cangrelor
Acute Coronary Syndrome (ACS)
Primary: Stage I: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60% as Reported by the VerifyNow P2Y12 Point of Care Assay…
Phase 2 N=205 Remote Ischemic Preconditioning Prior to Vascular Surgery
Peripheral Arterial Disease · Vascular Surgery
Primary: Troponin I Elevation Above the Upper Reference Limit (URL) — 25; 22 participants
N/A N=200 Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
Stable Angina
Primary: Exercise Time on Treadmill — 28.4; 11.8 seconds